None
Quote | Entera Bio Ltd. (NASDAQ:ENTX)
Last: | $2.01 |
---|---|
Change Percent: | 0.5% |
Open: | $1.97 |
Close: | $2 |
High: | $2.0299 |
Low: | $1.97 |
Volume: | 16,041 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Entera Bio Ltd. (NASDAQ:ENTX)
2024-04-12 10:00:50 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Drug...
JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tab...
Message Board Posts | Entera Bio Ltd. (NASDAQ:ENTX)
Subject | By | Source | When |
---|---|---|---|
Monday should be even better for this ticker | harry crumb | investorshub | 03/04/2023 5:45:44 AM |
Entera Bio Announces FDA Agreement for a Single | midastouch017 | investorshub | 10/06/2022 12:52:32 PM |
10% looking good for a break out of | interloper | investorshub | 08/09/2021 7:52:35 PM |
AviseAnalytics: $ENTX ENTERA BIO: A GAME CHANGER IN OSTEOPOROSIS IN THE OFFING! In | AviseAnalytics | investorshangout | 06/25/2021 12:18:13 PM |
Either or made money, hope all do. I'll | make it happen | investorshub | 06/24/2021 7:18:58 PM |
News, Short Squeeze, Breakout and More Instantly...
Entera Bio Ltd. Company Name:
ENTX Stock Symbol:
NASDAQ Market:
JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tab...
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 202...
JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary ...